会员登录 - 用户注册 - 设为首页 - 加入收藏 - 网站地图 【can carpenter ants sting】Antibodies, Protein-based Vaccines, Anti-virals, and Cell-based Therapies to Lead the Development of COVID-19 Treatment Pipeline- Exclusive Report by Meticulous Research®!

【can carpenter ants sting】Antibodies, Protein-based Vaccines, Anti-virals, and Cell-based Therapies to Lead the Development of COVID-19 Treatment Pipeline- Exclusive Report by Meticulous Research®

时间:2024-09-29 12:29:15 来源:hyperspeed loans login 作者:Hotspot 阅读:726次

London,can carpenter ants sting June 01, 2020 (GLOBE NEWSWIRE) -- According to a new market research report

【can carpenter ants sting】Antibodies, Protein-based Vaccines, Anti-virals, and Cell-based Therapies to Lead the Development of COVID-19 Treatment Pipeline- Exclusive Report by Meticulous Research®


COVID-19 (Coronavirus) Impact Assessment

【can carpenter ants sting】Antibodies, Protein-based Vaccines, Anti-virals, and Cell-based Therapies to Lead the Development of COVID-19 Treatment Pipeline- Exclusive Report by Meticulous Research®


: Health and Life Sciences (Coronavirus, Epidemiology, Economic Impact), Product Pipeline (Diagnosis (PCR Testing, Antibody testing), Treatment (Immunotherapy, Vaccines, Antiviral, Cell-based, Plasma therapy), and Geography”

【can carpenter ants sting】Antibodies, Protein-based Vaccines, Anti-virals, and Cell-based Therapies to Lead the Development of COVID-19 Treatment Pipeline- Exclusive Report by Meticulous Research®


, published by Meticulous Research


®


, the antibodies, protein-based vaccines, anti-viral, cell-based therapies are expected to lead the COVID-19 treatment pipeline.


Download Free Sample Report Now @


https://www.meticulousresearch.com/download-sample-report/cp_id=5098


The high transmission rate of coronavirus that lead to rapid increase in COVID-19 cases and deaths world-wide, triggered the rapid growth in diagnostic and treatment needs. However, lack of information on the novel virus such as biological, genetic information, duration of immunity granted in recovered patients, among others, which is vital to develop a safe & effective treatment option, has been a key challenge in achieving a successful solution.


With the growing cases of COVID-19 and its impact on the healthcare industry, this report analyses the diagnosis and treatments areas widely. The diagnosis segment is further divided into PCR-based testing and antibody testing; whereas, the treatment area is segmented into vaccines, immunotherapies, anti-virals, cell-based therapies, and other therapies. Vaccines and anti-virals are the most explored treatment options currently being investigated by researchers worldwide. The study also evaluates product pipeline based on development stage.


COVID-19 crisis has affected various countries differently based on traveller volumes, responsiveness of government to the infections, and capabilities of healthcare systems, among other factors. Geographically, North America has been the most affected region, primarily attributed to the U.S. being the most affected country having most number of confirmed cases as well as deaths, globally (as of 25


th


May 2020). Other most affected nations include the U.K., Spain, France, Italy, Brazil, and Germany among others. Further, almost all the affected nations have experienced rapid economic decline leading GDP decline, increase in unemployment rates, and increase in inflation rates.


Speak to our Analysts to Understand the Impact of COVID-19 on Your Business:


https://www.meticulousresearch.com/download-sample-report/cp_id=5098


The governments across the globe are implementing actions to overcome the situation. Primary focus has been restriction on people movement, setting up emergency screens and treatment centres, creating mass awareness, and accelerating research and development for COVID-19. For instance, in the U.S., the Biomedical Advanced Research and Development Authority (BARDA), a federal agency that funds disease-fighting technology, has stated an investment of nearly USD 1 billion to support coronavirus vaccine development. Similarly, the U.K.’s National Health Services (NHS) announced GBP 24.6 million funding as a part of rapid research responses.


Some of the key players engaged in the COVID-19 diagnosis and treatment development include Roche Holding AG (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), AbbVie Corporation (U.S.), Gilead Sciences, Inc. (U.S.), Eli Lilly and Company (U.S.), Moderna, Inc. (U.S.), Novavax, Inc. (U.S.), Medicago, Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline (U.K.), Sanofi S.A. (France), Johnson & Johnson (U.S.), Sorrento Therapeutics, Inc. (U.S.), AstraZeneca Plc (U.K.), Pfizer, Inc. (U.S.), CTI Biopharma Corporation (U.S.), OncoImmune, Inc. (U.S.), Athersys, Inc. (U.S.), Celularity, Inc. (U.S.), Pluristem Therapeutics (Israel), and Takeda Pharmaceuticals Company Ltd (Japan), among others.


Click here to get the short-term and long-term impact of COVID-19 on this Market.


Please visit:


https://www.meticulousresearch.com/product/COVID-19-impact-assessment-health-and-life-sciences-industry-5098/


Scope of the Report:


COVID-19 Product Pipeline


Diagnosis


PCR Testing


Antibody Testing


Treatment


Vaccines


Immunotherapy


Antiviral


Cell-based Therapy


Other Therapies


COVID-19: Impact on Healthcare Industry


Diagnostics


Rapid Test Kits


PCR / Rapid Antigen Testing / Nucleic Acid-Based Tests


Advantages Offered by PCR Testing in COVID -19 Diagnosis


Restraints


Key Companies


Antibody Testing / Serological Testing


Advantages Over Molecular Tests


Use of Antibody Testing for Herd Immunity Analysis and Easing Lock-Down


Restraints


Key Companies


Therapies


Vaccines


Immunotherapies (Antibodies)


Monoclonal Antibody


T-Cell Therapy


Potential Game Changers: Antibodies


Ilaris (Canakinumab)


Sylvant (Siltuximab)


Lenzilumab


Ultomiris (Ravulizumab-Cwvz)


Tocilizumab


Anti-Virals


Potential Game Changers


Chloroquine and Hydroxychloroquine (HCQ)


Remdesivir


Cell-Based Therapies


Other Therapies


Plasma Therapy


Devices


COVID-19 Industry Impact Assessment, by Geography


North America


Europe


Asia-Pacific (APAC)


Rest of the World (RoW)


Download Free Sample Report Now @


https://www.meticulousresearch.com/download-sample-report/cp_id=5098


Amidst this crisis, Meticulous Research


®


is continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to. assess the impact of COVID-19 on any industry here-


https://www.meticulousresearch.com/custom-research.php


Related Reports:


Infectious Disease Diagnostics Market


by Product and Solution (Consumables, System, Software and Services), Technology (Immunodiagnostics, PCR, INAAT), Disease (HIV, HAIS, Influenza), End User (Hospital, Reference Lab, Research) - Global Forecast to 2027


Vaccines Market


by Indication (Influenza, Rotavirus, DTP Vaccines), Route of Administration (Intramuscular, Subcutaneous, Oral), Type/Antigen (Conjugate Vaccine, Live Attenuated Vaccine), Valence (Multivalent, Monovalent Vaccines) - Global Forecast to 2027


Ventilators Market


by Product (Instruments, Accessories), Mobility (Intensive Care, Portable), Interface (Invasive, Non-invasive), Age Group (Adult, Pediatric), Mode (Volume, Pressure, Dual), End User (Hospital, ASCs, Home Care) – Global Forecast to 2027


Point of Care Molecular Diagnostics Market


by Product and Solution (Assay, Analyzer, Software, Services), Technology (RT-qPCR, INAAT), Application (Respiratory Diseases, Hospital Acquired Infections, STD), and End User - Global Forecast to 2027


Medical/Hospital Beds Market


by Product (Bed, Accessories), Technology (Power, Manual), Type of Care (Curative, Rehabilitation), Healthcare Facilities (Critical, Bariatric, Long-term, Paediatric, Maternal, Home Care) - Global Forecast to 2027


About Meticulous Research®


The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze and present the critical market data with great attention to details.


Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, with the help of its unique research methodologies, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa regions.


With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.


Mr. Khushal Bombe


Meticulous Research®


Direct Lines: +1-646-781-8004 (North America)


+44-203-868-8738 (Europe)


+91 744-7780008 (Asia-Pacific)


Email- [email protected]


Visit Our Website: https://www.meticulousresearch.com/


Meticulous Research® Blog: https://meticulousblog.org/


Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research


View comments


(责任编辑:Hotspot)

相关内容
  • Here's Why We're Not Too Worried About Luxxu Group's (HKG:1327) Cash Burn Situation
  • Pfizer commits to UK research hub in Astra battle
  • Nabors Industries Ltd (NBR) Files 10-K for the Fiscal Year Ended on December 31, 2018
  • Higher drug prices ring in the new year for more than 250 pharmaceuticals
  • Hedge Funds Souring On E*TRADE Financial (ETFC)
  • Is 2019 the Year Lawyers Finally Learn Their Lesson About Technology?
  • American Assets Trust Inc (AAT) Chairman, CEO & President Ernest S Rady Bought $430,471 of ...
  • One Thing To Remember About The Peking University Resources (Holdings) Company Limited (HKG:618) Share Price
推荐内容
  • Apple Tells Staff U.S. Stores to Remain Closed Until Early May
  • Oil Stocks: 3 Bold Predictions for 2019
  • YUM! Brands Strategic Plans Bode Well: Should You Hold?
  • ENDRA Life Sciences Issues Shareholder Letter
  • Is MYR Group (MYRG) a Great Value Stock Right Now?
  • Study finds that Vermont is top state for inbound moves